Breaking Advances
Cancer Res November 15 2010 70 (22) 8971-8972; DOI:10.1158/0008-5472.CAN-70-22-BA
Table of Contents
Breaking Advances
Reviews
- ReviewsHannah Harrison, Gillian Farnie, Keith R. Brennan and Robert B. ClarkeCancer Res November 15 2010 70 (22) 8973-8976; DOI:10.1158/0008-5472.CAN-10-1559
- ReviewsMo Chen, Jian Zhang and James L. ManleyCancer Res November 15 2010 70 (22) 8977-8980; DOI:10.1158/0008-5472.CAN-10-2513
Priority Reports
- Priority Reports | Free ArticleMeghan J. Seltzer, Bryson D. Bennett, Avadhut D. Joshi, Ping Gao, Ajit G. Thomas, Dana V. Ferraris, Takashi Tsukamoto, Camilo J. Rojas, Barbara S. Slusher, Joshua D. Rabinowitz, Chi V. Dang and Gregory J. RigginsCancer Res November 15 2010 70 (22) 8981-8987; DOI:10.1158/0008-5472.CAN-10-1666
IDH1 mutations create a higher dependence of glioma cells on α-ketoglutarate, relative to normal cells, that could be therapeutically exploited by targeting glutamine metabolism.
- Priority ReportsJagadish C. Ghosh, Markus D. Siegelin, Takehiko Dohi and Dario C. AltieriCancer Res November 15 2010 70 (22) 8988-8993; DOI:10.1158/0008-5472.CAN-10-2225
Findings implicate a chaperone network in controlling mitochondrial permeability transition and apoptosis in cancer cells.
Clinical Studies
- Clinical StudiesR. Jeffrey Karnes, John C. Cheville, Cristiane M. Ida, Thomas J. Sebo, Asha A. Nair, Hui Tang, Jan-Marie Munz, Farhad Kosari and George VasmatzisCancer Res November 15 2010 70 (22) 8994-9002; DOI:10.1158/0008-5472.CAN-10-1358
The study presents TOP2A as a superior prognostic marker for prostate cancer and shows that its predictive ability is dependent on cancer subtype.
- Clinical StudiesVictoria A. Brown, Ketan R. Patel, Maria Viskaduraki, James A. Crowell, Marjorie Perloff, Tristan D. Booth, Grygoriy Vasilinin, Ananda Sen, Anna Maria Schinas, Gianfranca Piccirilli, Karen Brown, William P. Steward, Andreas J. Gescher and Dean E. BrennerCancer Res November 15 2010 70 (22) 9003-9011; DOI:10.1158/0008-5472.CAN-10-2364
This study defines suitable doses, accompanying blood levels, and potential efficacy biomarkers which might help to optimize future cancer chemoprevention intervention studies of the red wine constituent resveratrol.
Integrated Systems and Technologies
- Integrated Systems and TechnologiesErika R. Amstalden van Hove, Tiffany R. Blackwell, Ivo Klinkert, Gert B. Eijkel, Ron M.A. Heeren and Kristine GlundeCancer Res November 15 2010 70 (22) 9012-9021; DOI:10.1158/0008-5472.CAN-10-0360
Mass spectrometry imaging techniques can identify different tissue microenvironments in breast tumors, possibly improving their clinicopathological assessment in the future.
- Integrated Systems and TechnologiesCarsten H. Nielsen, Richard H. Kimura, Nadia Withofs, Phuoc T. Tran, Zheng Miao, Jennifer R. Cochran, Zhen Cheng, Dean Felsher, Andreas Kjær, Juergen K. Willmann and Sanjiv S. GambhirCancer Res November 15 2010 70 (22) 9022-9030; DOI:10.1158/0008-5472.CAN-10-1338
Methods that improve PET imaging in cancer offer opportunities for improved detection and management.
Microenvironment and Immunology
- Microenvironment and ImmunologySebastian Kreiter, Abderraouf Selmi, Mustafa Diken, Michael Koslowski, Cedrik M. Britten, Christoph Huber, Özlem Türeci and Ugur SahinCancer Res November 15 2010 70 (22) 9031-9040; DOI:10.1158/0008-5472.CAN-10-0699
Findings define methods to achieve strong antigen-specific immunity and cancer cures using antigen-encoding RNA in preclinical animal models.
- Microenvironment and ImmunologyAngela D. Pardee, Dustin McCurry, Sean Alber, Peisheng Hu, Alan L. Epstein and Walter J. StorkusCancer Res November 15 2010 70 (22) 9041-9052; DOI:10.1158/0008-5472.CAN-10-1369
Correcting tumoral immune escape exerts therapeutic effects against established tumors by improving the delivery of antitumor T cells into the tumor microenvironment.
- Microenvironment and ImmunologyYangbing Zhao, Edmund Moon, Carmine Carpenito, Chrystal M. Paulos, Xiaojun Liu, Andrea L. Brennan, Anne Chew, Richard G. Carroll, John Scholler, Bruce L. Levine, Steven M. Albelda and Carl H. JuneCancer Res November 15 2010 70 (22) 9053-9061; DOI:10.1158/0008-5472.CAN-10-2880
Findings offer preclinical proof-of-concept for a novel adoptive T cell transfer approach for cancer treatment that can potentiate antitumor effects and complement approaches using retroviral and lentiviral engineered T-cell therapies.
- Microenvironment and ImmunologyRoberta Zappasodi, Serenella M. Pupa, Gaia C. Ghedini, Italia Bongarzone, Michele Magni, Antonello D. Cabras, Mario P. Colombo, Carmelo Carlo-Stella, Alessandro M. Gianni and Massimo Di NicolaCancer Res November 15 2010 70 (22) 9062-9072; DOI:10.1158/0008-5472.CAN-10-1825
Clinical findings confirm expectations of a stringent correlation between the therapeutic efficacy of a dendritic cell vaccine and the extent of immunogenic death induced in the tumor cells used to load the dendritic cells before vaccination.
- Microenvironment and ImmunologyCornelis A.M. Van Bergen, Caroline E. Rutten, Edith D. Van Der Meijden, Simone A.P. Van Luxemburg-Heijs, Ellie G.A. Lurvink, Jeanine J. Houwing-Duistermaat, Michel G.D. Kester, Arend Mulder, Roel Willemze, J.H. Frederik Falkenburg and Marieke GriffioenCancer Res November 15 2010 70 (22) 9073-9083; DOI:10.1158/0008-5472.CAN-10-1832
In this study, efficient T-cell selection was combined with SNP genotyping to discover a significant number of new minor histocompatibility antigens that can be targeted by cellular immunotherapy of cancer.
Molecular and Cellular Pathobiology
- Molecular and Cellular PathobiologyPankaj Taneja, Dejan Maglic, Fumitake Kai, Takayuki Sugiyama, Robert D. Kendig, Donna P. Frazier, Mark C. Willingham and Kazushi InoueCancer Res November 15 2010 70 (22) 9084-9094; DOI:10.1158/0008-5472.CAN-10-0159
Mechanistic findings define a transcriptional cascade that plays a critical role in quenching HER2/neu oncogenic signals known to promote breast cancer.
- Molecular and Cellular PathobiologyTatsuhiro Shibata, Shigeru Saito, Akiko Kokubu, Takafumi Suzuki, Masayuki Yamamoto and Setsuo HirohashiCancer Res November 15 2010 70 (22) 9095-9105; DOI:10.1158/0008-5472.CAN-10-0384
Findings offer a rationale to target a master transcriptional regulator of antioxidant genes and Phase II detoxifying enzymes as an anticancer strategy, also suggesting it as a novel theranostic biomarker.
- Molecular and Cellular PathobiologyReema S. Wahdan-Alaswad, Kyung Song, Tracy L. Krebs, Dorjee T.N. Shola, Jose A. Gomez, Shigemi Matsuyama and David DanielpourCancer Res November 15 2010 70 (22) 9106-9117; DOI:10.1158/0008-5472.CAN-10-1119
Findings elucidate how a key growth factor in prostate cancer acts at several levels to shut down a central pathway of epithelial cell function in the prostate, with important therapeutic implications for prostate cancer management.
- Molecular and Cellular PathobiologyLi-hui Wang, Jin Xiang, Min Yan, Yan Zhang, Yan Zhao, Cai-feng Yue, Jie Xu, Fei-meng Zheng, Jin-na Chen, Zhuang Kang, Tong-sheng Chen, Da Xing and Quentin LiuCancer Res November 15 2010 70 (22) 9118-9128; DOI:10.1158/0008-5472.CAN-10-1246
An important mitotic kinase that is targeted by small molecule inhibitors currently in clinical testing is found to have an important role in supporting metastasis.
- Molecular and Cellular PathobiologyDanny Yakoub, Hector C. Keun, Robert Goldin and George B. HannaCancer Res November 15 2010 70 (22) 9129-9136; DOI:10.1158/0008-5472.CAN-10-1566
Esophageal cancer can be detected by metabolic profiling of adjacent histologically normal mucosa.
- Molecular and Cellular PathobiologyWang-Xia Wang, Natasha Kyprianou, Xiaowei Wang and Peter T. NelsonCancer Res November 15 2010 70 (22) 9137-9142; DOI:10.1158/0008-5472.CAN-10-1684
Findings elucidate microRNA-mediated control of a common mitogen in a variety of human cancers, the regulation of which had been previously obscure, with implications for microRNA-based therapeutic targeting.
- Molecular and Cellular PathobiologyCassandra R. Diegel, Kathleen R. Cho, Adel K. El-Naggar, Bart O. Williams and Charlotta LindvallCancer Res November 15 2010 70 (22) 9143-9152; DOI:10.1158/0008-5472.CAN-10-1758
Findings report a novel preclinical model and a rationale to evaluate rapamycin therapy for salivary gland acinic cell carcinoma, a low grade neoplasm but one that tends to recur.
- Molecular and Cellular PathobiologyHouman Ashrafian, Linda O'Flaherty, Julie Adam, Violetta Steeples, Yuen-Li Chung, Phil East, Sakari Vanharanta, Heli Lehtonen, Emma Nye, Emine Hatipoglu, Melroy Miranda, Kimberley Howarth, Deepa Shukla, Helen Troy, John Griffiths, Bradley Spencer-Dene, Mohammed Yusuf, Emanuela Volpi, Patrick H. Maxwell, Gordon Stamp, Richard Poulsom, Christopher W. Pugh, Barbara Costa, Chiara Bardella, Maria Flavia Di Renzo, Michael I. Kotlikoff, Virpi Launonen, Lauri Aaltonen, Mona El-Bahrawy, Ian Tomlinson and Patrick J. PollardCancer Res November 15 2010 70 (22) 9153-9165; DOI:10.1158/0008-5472.CAN-10-1949
Fumarate hydratase deficiency compels cells to prematurely adopt a metabolic phenotype that predisposes them to cell proliferation and growth and ultimately to cancer.
- Molecular and Cellular PathobiologyK-John J. Cheung, Nathalie A. Johnson, Joslynn G. Affleck, Tesa Severson, Christian Steidl, Susana Ben-Neriah, Jacqueline Schein, Ryan D. Morin, Richard Moore, Sohrab P. Shah, Hong Qian, Jessica E. Paul, Adele Telenius, Thomas Relander, Wan Lam, Kerry Savage, Joseph M. Connors, Carolyn Brown, Marco A. Marra, Randy D. Gascoyne and Douglas E. HorsmanCancer Res November 15 2010 70 (22) 9166-9174; DOI:10.1158/0008-5472.CAN-10-2460
Findings identify a candidate genetic marker of prognosis in follicular lymphoma, which may provide an explanation as to why its treatment with rituximab provides less benefit in some patients.
- Molecular and Cellular PathobiologyPedro de Souza Rocha Simonini, Achim Breiling, Nibedita Gupta, Mahdi Malekpour, Mahmoud Youns, Ramesh Omranipour, Fatemeh Malekpour, Stefano Volinia, Carlo M. Croce, Hossein Najmabadi, Sven Diederichs, Özgür Sahin, Doris Mayer, Frank Lyko, Jörg D. Hoheisel and Yasser RiazalhosseiniCancer Res November 15 2010 70 (22) 9175-9184; DOI:10.1158/0008-5472.CAN-10-1318
Findings offer significant new insights into how the estrogen receptor is deregulated in breast cancer.
- Molecular and Cellular PathobiologyJacqueline C. Shultz, Rachel W. Goehe, D. Shanaka Wijesinghe, Charuta Murudkar, Amy J. Hawkins, Jerry W. Shay, John D. Minna and Charles E. ChalfantCancer Res November 15 2010 70 (22) 9185-9196; DOI:10.1158/0008-5472.CAN-10-1545
Findings define a functionally important alternative splicing mechanism in lung adenocarcinoma that offers a novel approach to therapeutic development.
- Molecular and Cellular PathobiologyYinfei Tan, Mitchell Cheung, Jianming Pei, Craig W. Menges, Andrew K. Godwin and Joseph R. TestaCancer Res November 15 2010 70 (22) 9197-9206; DOI:10.1158/0008-5472.CAN-10-1568
Findings define a homeobox protein that positively modifies a variety of oncogenic signals in ovarian cancer, with potential prognostic applications.
- Molecular and Cellular PathobiologyYanrong Su, Jarah A. Meador, Gloria M. Calaf, Luca Proietti De-Santis, Yongliang Zhao, Vilhelm A. Bohr and Adayabalam S. BalajeeCancer Res November 15 2010 70 (22) 9207-9217; DOI:10.1158/0008-5472.CAN-10-1743
Study implicates a DNA helicase regulated by Rb-E2F as an important driver of metastatic progression of prostate cancer.
Prevention and Epidemiology
- Prevention and EpidemiologyAlison M. Mondul, Stephanie J. Weinstein, Satu Männistö, Kirk Snyder, Ronald L. Horst, Jarmo Virtamo and Demetrius AlbanesCancer Res November 15 2010 70 (22) 9218-9223; DOI:10.1158/0008-5472.CAN-10-0985
Accumulating evidence argues that serum levels of vitamin D exert a profound influence on cancer risk, as illustrated in this study of bladder cancer.
- Prevention and EpidemiologyStella Koutros, Laura E. Beane Freeman, Sonja I. Berndt, Gabriella Andreotti, Jay H. Lubin, Dale P. Sandler, Jane A. Hoppin, Kai Yu, Qizhai Li, Laura A. Burdette, Jeffrey Yuenger, Meredith Yeager and Michael C.R. AlavanjaCancer Res November 15 2010 70 (22) 9224-9233; DOI:10.1158/0008-5472.CAN-10-1078
Study offers an excellent illustration of how an environmental modifier can radically alter the impact of a genetic risk marker on a patient's susceptibilty to disease.
Therapeutics, Targets, and Chemical Biology
- Therapeutics, Targets, and Chemical BiologyRamtin Rahmanzadeh, Prakash Rai, Jonathan P. Celli, Imran Rizvi, Bettina Baron-Lühr, Johannes Gerdes and Tayyaba HasanCancer Res November 15 2010 70 (22) 9234-9242; DOI:10.1158/0008-5472.CAN-10-1190
A common immunohistopathological marker used for staging of clinical cancers may offer unexpected opportunities as a therapeutic target.
- Therapeutics, Targets, and Chemical BiologyNathalie Gaspar, Lynley Marshall, Lara Perryman, Dorine A. Bax, Suzanne E. Little, Marta Viana-Pereira, Swee Y. Sharp, Gilles Vassal, Andrew D.J. Pearson, Rui M. Reis, Darren Hargrave, Paul Workman and Chris JonesCancer Res November 15 2010 70 (22) 9243-9252; DOI:10.1158/0008-5472.CAN-10-1250
Findings identify a reversible novel mechanism of resistance to the alkylating agent temozolomide in pediatric glioblastoma model systems and patient samples.
- Therapeutics, Targets, and Chemical BiologyGuillaume Ploussard, Stéphane Terry, Pascale Maillé, Yves Allory, Nanor Sirab, Laurence Kheuang, Pascale Soyeux, Nathalie Nicolaiew, Estelle Coppolani, Bernard Paule, Laurent Salomon, Stéphane Culine, Ralph Buttyan, Francis Vacherot and Alexandre de la TailleCancer Res November 15 2010 70 (22) 9253-9264; DOI:10.1158/0008-5472.CAN-10-1447
Findings suggest a novel theranostic molecule in advanced prostate cancer to predict responses to taxane therapy and to improve treatment of taxane-resistant disease.
- Therapeutics, Targets, and Chemical BiologyVaibhav Kapuria, Luke F. Peterson, Dexing Fang, William G. Bornmann, Moshe Talpaz and Nicholas J. DonatoCancer Res November 15 2010 70 (22) 9265-9276; DOI:10.1158/0008-5472.CAN-10-1530
An antitumor compound previously found to block signaling by Jak2 kinase is found to target deubiquitinases that are commonly overexpressed in cancer cells.
- Therapeutics, Targets, and Chemical Biology | Free ArticleFreddy E. Escorcia, Erik Henke, Michael R. McDevitt, Carlos H. Villa, Peter Smith-Jones, Ronald G. Blasberg, Robert Benezra and David A. ScheinbergCancer Res November 15 2010 70 (22) 9277-9286; DOI:10.1158/0008-5472.CAN-10-2029
A novel approach to remodel the tumor vasculature has strongly positive pharmacokinetic consequences on cancer drug delivery in a preclinical model, resulting in better therapy and survival outcomes.
- Therapeutics, Targets, and Chemical BiologyYouyou Zhao, Declan McLaughlin, Emma Robinson, Adam P. Harvey, Michelle B. Hookham, Ajay M. Shah, Barbara J. McDermott and David J. GrieveCancer Res November 15 2010 70 (22) 9287-9297; DOI:10.1158/0008-5472.CAN-10-2664
A major ROS-producing enzyme in the heart is implicated in adverse cardiac remodeling caused by doxorubicin chemotherapy, implying a new therapeutic strategy to reduce doxorubicin cardiotoxicity.
- Therapeutics, Targets, and Chemical BiologyMary A. Dwyer, James D. Joseph, Hilary E. Wade, Matthew L. Eaton, Rebecca S. Kunder, Dmitri Kazmin, Ching-yi Chang and Donald P. McDonnellCancer Res November 15 2010 70 (22) 9298-9308; DOI:10.1158/0008-5472.CAN-10-0226
Results define an autocrine mechanism controlled by the nuclear receptor ERRα, associated with poor outcomes in several cancers, that influences cancer cell migratory capacity.
- Therapeutics, Targets, and Chemical BiologyDa-Liang Ou, Ying-Chun Shen, Sung-Liang Yu, Kuen-Feng Chen, Pei-Yen Yeh, Hsiang-Hsuan Fan, Wen-Chi Feng, Ching-Tzu Wang, Liang-In Lin, Chiun Hsu and Ann-Lii ChengCancer Res November 15 2010 70 (22) 9309-9318; DOI:10.1158/0008-5472.CAN-10-1033
Mechanistic findings suggest a potential surrogate marker that could be useful to predict the efficacy of Sorafenib in liver cancer.
- Therapeutics, Targets, and Chemical BiologyImran Rizvi, Jonathan P. Celli, Conor L. Evans, Adnan O. Abu-Yousif, Alona Muzikansky, Brian W. Pogue, Dianne Finkelstein and Tayyaba HasanCancer Res November 15 2010 70 (22) 9319-9328; DOI:10.1158/0008-5472.CAN-10-1783
A 3D model for ovarian micrometastases is introduced as a high-throughput platform to report treatment response, exemplified in this study to show how photodynamic therapy synergistically enhances carboplatin efficacy.
- Therapeutics, Targets, and Chemical BiologySarah J.E. Wong-Goodrich, Madeline L. Pfau, Catherine T. Flores, Jennifer A. Fraser, Christina L. Williams and Lee W. JonesCancer Res November 15 2010 70 (22) 9329-9338; DOI:10.1158/0008-5472.CAN-10-1854
Studies in mice suggest that voluntary exercise can alleviate progressive memory loss after cranial irradiation, strongly prompting studies in clinical settings.
- Therapeutics, Targets, and Chemical BiologyShinji Kuroda, Toshiya Fujiwara, Yasuhiro Shirakawa, Yasumoto Yamasaki, Shuya Yano, Futoshi Uno, Hiroshi Tazawa, Yuuri Hashimoto, Yuichi Watanabe, Kazuhiro Noma, Yasuo Urata, Shunsuke Kagawa and Toshiyoshi FujiwaraCancer Res November 15 2010 70 (22) 9339-9348; DOI:10.1158/0008-5472.CAN-10-2333
Results illustrate the potential of combining engineered oncolytic virotherapy and ionizing radiation as a strategy to improve the management of human cancer.
Tumor and Stem Cell Biology
- Tumor and Stem Cell BiologyBeatriz Escobar, Guillermo de Cárcer, Gonzalo Fernández-Miranda, Alberto Cascón, José J. Bravo-Cordero, María C. Montoya, Mercedes Robledo, Marta Cañamero and Marcos MalumbresCancer Res November 15 2010 70 (22) 9349-9359; DOI:10.1158/0008-5472.CAN-09-4491
Genetic ablation of Brick1, a component of the Wave/Scar actin regulatory complex, appears to exert a protective effect against malignant development in renal cancer and other cancers where loss occurs.
- Tumor and Stem Cell BiologyFei Zhang, Xiaofang Zhang, Menghui Li, Peng Chen, Bin Zhang, Hua Guo, Wenfeng Cao, Xiying Wei, Xuchen Cao, Xishan Hao and Ning ZhangCancer Res November 15 2010 70 (22) 9360-9370; DOI:10.1158/0008-5472.CAN-10-0207
Findings illuminate understanding of how EGF activates the mTORC2 growth regulatory complex to drive breast cancer metastasis, with implications for clinical studies of mTOR inhibitors.
- Tumor and Stem Cell BiologyYuan Wan, Young-tae Kim, Na Li, Steve K. Cho, Robert Bachoo, Andrew D. Ellington and Samir M. IqbalCancer Res November 15 2010 70 (22) 9371-9380; DOI:10.1158/0008-5472.CAN-10-0568
More sensitive and specific tumor detection technologies are needed to rapidly assess surgical resection margins and to monitor residual tumor cells that may persist in blood after disease treatment.
- Tumor and Stem Cell BiologyShinji Takeuchi, Akiko Takahashi, Noriko Motoi, Shin Yoshimoto, Tomoko Tajima, Kimi Yamakoshi, Atsushi Hirao, Shigeru Yanagi, Kiyoko Fukami, Yuichi Ishikawa, Saburo Sone, Eiji Hara and Naoko OhtaniCancer Res November 15 2010 70 (22) 9381-9390; DOI:10.1158/0008-5472.CAN-10-0801
Expectations that mice lacking both the p16INK4 and p21WAF1 tumor suppressor genes would be highly susceptible to carcinogenesis is experimentally confirmed and mechanistically dissected in this study.
- Tumor and Stem Cell BiologyFalko Hochgräfe, Luxi Zhang, Sandra A. O'Toole, Brigid C. Browne, Mark Pinese, Ana Porta Cubas, Gillian M. Lehrbach, David R. Croucher, Danny Rickwood, Alice Boulghourjian, Robert Shearer, Radhika Nair, Alexander Swarbrick, Dana Faratian, Peter Mullen, David J. Harrison, Andrew V. Biankin, Robert L. Sutherland, Mark J. Raftery and Roger J. DalyCancer Res November 15 2010 70 (22) 9391-9401; DOI:10.1158/0008-5472.CAN-10-0911
Phosphoproteomic profiling reveals that basal breast cancer cells are characterized by an extensive Src family kinase signalling network, highlighting candidate theranostic targets for this aggresive subtype of breast cancers.
- Tumor and Stem Cell BiologyEkaterina V. Kalashnikova, Alexey S. Revenko, Abigael T. Gemo, Nicolas P. Andrews, Clifford G. Tepper, June X. Zou, Robert D. Cardiff, Alexander D. Borowsky and Hong-Wu ChenCancer Res November 15 2010 70 (22) 9402-9412; DOI:10.1158/0008-5472.CAN-10-1199
Findings suggest that the prognostic significance of a chromatin coregulator for hormone receptors in breast cancer is based on its role in integrating multiple oncogenic programs, with particular importance to aggressive triple-negative tumors.
- Tumor and Stem Cell BiologyMarta Canel, Alan Serrels, Derek Miller, Paul Timpson, Bryan Serrels, Margaret C. Frame and Valerie G. BruntonCancer Res November 15 2010 70 (22) 9413-9422; DOI:10.1158/0008-5472.CAN-10-1454
Results identify a novel role for FAK and Src in regulating tumor cell movement in vivo using fluorescence based microscopy.
- Tumor and Stem Cell BiologyMathieu Darsigny, Jean-Philippe Babeu, Ernest G. Seidman, Fernand-Pierre Gendron, Emile Levy, Julie Carrier, Nathalie Perreault and François BoudreauCancer Res November 15 2010 70 (22) 9423-9433; DOI:10.1158/0008-5472.CAN-10-1697
Findings point to the nuclear receptor HNF4α as a potential therapeutic target to modify epithelial cell resistance to ROS production during intestinal tumorigenesis.
- Tumor and Stem Cell BiologyXiaobo Zhou and Karl MüngerCancer Res November 15 2010 70 (22) 9434-9443; DOI:10.1158/0008-5472.CAN-10-1960
Findings support the definition of a new tumor suppressor located at chromosome 13q14 and suggest its possible utility in predicting cancer chemosensitivity.
- Tumor and Stem Cell BiologyTao Lin, Lingjun Meng, Yi Li and Robert Y.L. TsaiCancer Res November 15 2010 70 (22) 9444-9452; DOI:10.1158/0008-5472.CAN-10-2159
Studies of a stem cell marker in breast cancer cells suggest its potential as a therapeutic target.
- Tumor and Stem Cell BiologyNicolas Willemarck, Evelien Rysman, Koen Brusselmans, Griet Van Imschoot, Frank Vanderhoydonc, Katrien Moerloose, Evelyne Lerut, Guido Verhoeven, Frans van Roy, Kris Vleminckx and Johannes V. SwinnenCancer Res November 15 2010 70 (22) 9453-9462; DOI:10.1158/0008-5472.CAN-10-2324
Findings suggest that characteristic elevations in lipogenesis in cancer cells contribute to tumor growth not by improving membrane biosynthesis, as commonly believed, but by modifying fundamental developmental signaling and cell polarity.
- Tumor and Stem Cell BiologyXiaojun Yang, Xiaojuan Lin, Xiaomin Zhong, Sippy Kaur, Ning Li, Shun Liang, Heini Lassus, Liping Wang, Dionyssios Katsaros, Kathleen Montone, Xia Zhao, Youcheng Zhang, Ralf Bützow, George Coukos and Lin ZhangCancer Res November 15 2010 70 (22) 9463-9472; DOI:10.1158/0008-5472.CAN-10-2388
Findings offer evidence that cancer stem cells may arise through cellular reprogramming-like mechanisms.
- Tumor and Stem Cell BiologyShi-Lung Lin, Donald C. Chang, Shao-Yao Ying, Davey Leu and David T.S. WuCancer Res November 15 2010 70 (22) 9473-9482; DOI:10.1158/0008-5472.CAN-10-2746
As the most abundant tumor suppressor microRNA in human embryonic stem cells, miR-302 offers an appealing focus for the development of a universal cancer therapeutic.
- Tumor and Stem Cell BiologyYasufumi Niinaka, Kiyoshi Harada, Masahiro Fujimuro, Masamitsu Oda, Arayo Haga, Misa Hosoki, Narikazu Uzawa, Naoya Arai, Satoshi Yamaguchi, Masashi Yamashiro and Avraham RazCancer Res November 15 2010 70 (22) 9483-9493; DOI:10.1158/0008-5472.CAN-09-3880
An enzyme that functions inside cells in glycolysis and gluconeogenesis has a second extracellular function that in cancer provides a critical support for invasive cell motility, EMT, and metastasis.
- Tumor and Stem Cell BiologyImmanual Joseph, Robert Tressler, Ekaterina Bassett, Calvin Harley, Christen M. Buseman, Preeti Pattamatta, Woodring E. Wright, Jerry W. Shay and Ning F. GoCancer Res November 15 2010 70 (22) 9494-9504; DOI:10.1158/0008-5472.CAN-10-0233
Findings offer preclinical proof-of-concept for a highly tractable and attractive new approach to target cancer stem cells in cancer therapy.
- Tumor and Stem Cell BiologyPankaj Kumar Mandal, Manuela Schneider, Pirkko Kölle, Peter Kuhlencordt, Heidi Förster, Heike Beck, Georg W. Bornkamm and Marcus ConradCancer Res November 15 2010 70 (22) 9505-9514; DOI:10.1158/0008-5472.CAN-10-1509
Findings offer preclinical proof-of-concept that simultaneous inhibition of more than one cellular antioxidant system could be highly effective in killing tumor cells via redox modifiers.
- Tumor and Stem Cell BiologyEmilios Gemenetzidis, Daniela Elena-Costea, Eric K. Parkinson, Ahmad Waseem, Hong Wan and Muy-Teck TehCancer Res November 15 2010 70 (22) 9515-9526; DOI:10.1158/0008-5472.CAN-10-2173
Results identify a transcription factor in the FOXM1 family that can hijack adult human stem cells to jump start cancer initiation.
Corrections
- CorrectionsCancer Res November 15 2010 70 (22) 9527-9527; DOI:10.1158/0008-5472.CAN-10-3495
- CorrectionsCancer Res November 15 2010 70 (22) 9527-9527; DOI:10.1158/0008-5472.CAN-10-3605
Retractions
- RetractionsCancer Res November 15 2010 70 (22) 9528-9528; DOI:10.1158/0008-5472.CAN-10-3461
- RetractionsCancer Res November 15 2010 70 (22) 9528-9528; DOI:10.1158/0008-5472.CAN-10-3462
- RetractionsCancer Res November 15 2010 70 (22) 9529-9529; DOI:10.1158/0008-5472.CAN-10-3463
November 2010
Volume 70, Issue 22
Volume 70, Issue 22
Issue Highlights
Jump to
Advertisement
